Akebia Therapeutics (AKBA) vs Immuneering (IMRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Immuneering (IMRX) has outperformed Akebia Therapeutics (AKBA) over the past year, losing 36.8% versus a loss of 70.4%. Over five years, AKBA leads with a -69.4% price change compared with -84.5% for IMRX. Immuneering is the larger company by market cap ($240.7 million vs $226.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AKBA | IMRX |
|---|---|---|
| Share price | $0.8189 | $3.72 |
| Market cap | $226.92M | $240.67M |
| 1-day change | -6.24% | -3.63% |
| YTD return | -45.75% | -41.34% |
| 1-year return | -70.39% | -36.82% |
| 5-year return | -69.35% | -84.47% |
| EPS (TTM) | $-0.12 | $-0.93 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.20 | $8.48 |
| 52-week low | $0.814 | $3.60 |
| Distance from 52-week high | -74.41% | -56.13% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +378.69% | +361.56% |
| Average volume | 6.13M | 694.54K |
| Shares outstanding | 277.11M | 64.70M |
| Employees | 194 | 57 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMRX has outperformed AKBA by 33.6 percentage points over the past year.
About Akebia Therapeutics
AKBA stock →Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD.
Health Care · Biotechnology: Pharmaceutical Preparations · 194 employees
About Immuneering
IMRX stock →Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs.
Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees
AKBA vs IMRX FAQ
Which is bigger, Akebia Therapeutics or Immuneering?
Immuneering (IMRX) is larger, with a market capitalization of $240.67M compared with $226.92M for Akebia Therapeutics (AKBA).
Which stock has performed better over the past year, AKBA or IMRX?
IMRX returned -36.82% over the past 12 months, compared with -70.39% for AKBA (price return, excluding dividends). Past performance does not predict future results.
Are Akebia Therapeutics and Immuneering in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.